SavedAdd your journal

Journals / Retina-Vitreus / 2015 / Cilt: 23 - Sayı: 1

Yaşa Bağlı Maküla Dejeneresansında Tedavi Stratejileri: Yeni Terminoloji Işığında Ne Zaman Ne Yapalım?

Süleyman KAYNAK
RUKİYE IŞIK AYDIN
MAHMUT KAYA
Pages
1–14
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
🔖

Cite This Article

KAYNAK, S., AYDIN, R. I., KAYA, M. (2015). Yaşa Bağlı Maküla Dejeneresansında Tedavi Stratejileri: Yeni Terminoloji Işığında Ne Zaman Ne Yapalım?. Retina-Vitreus, Cilt: 23 - Sayı: 1, 1–14. https://ajindex.com/articles/307891

References (15)

  1. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA 2004;291:1900-1. http://www.brightfocus.org/macular/about/understanding/facts.html.
  2. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual im- pairment in the year 2002. Bull World Health Organ 2004;82:844-51.
  3. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-re- lated macular degeneration in the United States. Arch Ophthalmol 2004;122:564-72.
  4. Chopdar A, Chakravarthy U, Verma D. Age related macular degene- ration. BMJ 2003;326:485-8.
  5. Kourlas H, Abrams P. Ranibizumab for the treatment of neo- vascular age-related macular degeneration: a review. Clin Ther 2007;29:1850-61.
  6. Smith W, Assink J, Klein R, et al. Risk factors fora ge-related ma- cular degeneration: pooled findings from three continents. Ophthal- molohy 2001;108:697-704.
  7. Kawasaki R, Yasuda M, Song SJ, et al. The prevelence of age-rela- ted macular degeneration in Asians: a systematic review and meta- analysis. Ophthalmology 2010;117:921-7.
  8. Klein R, Klein BE, Linton K. Prevalence of Age- related maculo- pathy. The Beaver Dam Eye Study. Ophthalmology 1992;99:933-43.
  9. Klein, R, Klein BE, Jensen, S., et al. The five year Incidence and progression of age related maculopathy: The Beaver Dam Eye Study. Ophthalmology 1997;104:7-21.
  10. Vingerling JR, Dielemans I, Hofman A, et al. The prevalence of age related maculopathy in the rotterdam study. Ophthalmology 1995;102:205-10. http://www.dunya.com/yuzde-8imiz-65-yas-ustu-222634h.htm.
  11. Bhopal, RS. Concepts of epidemiology. Oxford: Oxford University Press 2002.
  12. Wong T, Chakravarthy U, Klein R, et al. The natural history and prognosis of neovascular age-related macular gegeneration a syste- matic review of the literature and meta-analysis. Ophthalmology 2008;115:116-26. Sham Injection The injection of a placebo or agent that simulates a drug being administered in a clinical trial Segen's Medical Dictio- nary. © 2012
  13. Farlex, Inc. All rights reserved. Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-31.
  14. Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44.
  15. Regillo CD, Brown DM, Abraham P, Yue H, et al. Randomized, do- uble-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am